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Abstract: Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance
but high variable expressivity. NF1 is caused by loss-of-function mutations in the NF1 gene, a negative
regulator of the RAS-MAPK pathway. The NF1 gene has one of the highest mutation rates in human
disorders, which may explain the outbreak of independent de novo variants in the same family. Here,
we report the co-occurrence of pathogenic variants in the NF1 and SPRED1 genes in six families with
NF1 and Legius syndrome, using next-generation sequencing. In five of these families, we observed
the co-occurrence of two independent NF1 variants. All NF1 variants were classified as pathogenic,
according to the American College of Medical Genetics and Genomics and the Association for Molecular
Pathology (ACMG-AMP) guidelines. In the sixth family, one sibling inherited a complete deletion
of the NF1 gene from her mother and carried a variant of unknown significance in the SPRED1
gene. This variant was also present in her brother, who was diagnosed with Legius syndrome, a
differential diagnosis of NF1. This work illustrates the complexity of molecular diagnosis in a not-so-rare
genetic disease.
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1. Introduction
Neurofibromatosis type 1 (NF1; MIM#162200) is an autosomal dominant disease with a worldwide
incidence between 1 in 2500 and 1 in 3000 individuals [1]. Clinical features predominantly consist of
multiple café-au-lait spots (CALS), axillary or inguinal freckling, Lisch nodules, and neurofibromas
(NFs). Other symptoms can develop in some patients, such as optic pathway gliomas (OPGs), short
stature, or pseudarthrosis. Affected patients are predisposed to benign peripheral nervous tumors [2]
called plexiform neurofibromas (PNFs), which can transform into malignant peripheral nerve sheath
tumors (MPNSTs) in ~10% of cases [3]. The NF1 diagnosis relies on the National Institutes of Health
(NIH) clinical criteria [4]. NF1 is characterized by complete penetrance and great inter- and intrafamilial
variable expressivity [5].
More than 95% of NF1 cases [6] are caused by loss-of-function mutations in the NF1 gene
(MIM*613113), which is located at 17q11.2. NF1 comprises 57 constitutive and three alternative exons
and spans over ~350 kb. The 8454-nucleotide open reading frame of the NF1 gene (NM_00267.3) encodes
a 2818-amino-acid protein, neurofibromin, which shows tumor suppressor function [7] by negatively
regulating the RAS-MAPK pathway [8]. The NF1 gene shows one of the highest mutation rates [9], with
more than 2600 different pathogenic variants referenced in public databases (Leiden Open Variation
Database and Human Gene Mutation Database). About 50% of all NF1 cases are sporadic, i.e., due to
de novo mutations [10–12].
Some of the NF1 clinical features are common to other diseases, such as Legius syndrome
(MIM#611431), an autosomal dominant disorder characterized by the presence of multiple CALS,
sometimes associated with skinfold freckling and macrocephaly or learning disabilities. Legius
syndrome is caused by loss-of-function mutations in the SPRED1 gene (MIM*609291) [13–15].
The SPRED1 protein acts as a negative regulator of the RAS-MAPK pathway [16].
Here, we report the observation of six NF1 families. Surprisingly, the NF1 pathogenic variant
identified in the index cases was not present in all the other affected members of the family, thus
revealing the presence of a second independent NF1 pathogenic variant in the same family. In one
family, NF1 and Legius syndrome co-occurred in siblings, challenging the molecular diagnosis for
these patients. Our study aimed at highlighting the complexity of molecular diagnosis in NF1 families
where patients can carry distinct pathogenic variants or may present with phenocopies.
2. Materials and Methods
2.1. Study Samples
Informed consent was collected for all the patients and their relatives (ethical approval code:
Comités de protection des personnes CPP17/79, A0296746, and 2015-08-11DC). Samples were collected
on EDTA tubes for DNA analysis and on PAXgene™ Blood RNA Tubes (Becton Dickinson, Rungis,
France) for RNA analysis. All patients underwent a physical examination with a referent clinician
who recorded the phenotypic data according to a standardized questionnaire including: number
and size of CALS; number and localization of freckling; number and localization of plexiform and
spinal neurofibromas; number of cutaneous and subcutaneous neurofibromas, each classified into
quantitative categories of 0, 1–9, 10–99, and >100; the presence or absence of MPNSTs, Lisch nodules,
optic pathway gliomas, skeletal malformations, or developmental delay.
2.2. DNA and RNA Extractions
DNA extraction was performed with the Maxwell® 16 LEV Blood DNA Kit (Promega, Charbonnières-
les-Bains, France) on EDTA blood samples according to the manufacturer’s instructions. RNA was
directly extracted from 5 mL of PAXgeneTM blood samples with the PAXgeneTM Blood RNA System
(Qiagen, Courtaboeuf, France) according to the manufacturer’s instructions. DNA concentrations were
quantified using a NanoDrop 1000 Spectrophotometer v3.8 (Thermo Fisher Scientific, Courtaboeuf,
France).
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2.3. Microsatellite Typing
Four NF1 intragenic polymorphic microsatellites (D17S1307, D17S2163, D17S1166, and GDB:270136)
were studied for segregation analysis. Three additional NF1 extragenic polymorphic microsatellites
(D17S841, D17S1800, and D17S798) were also genotyped when the previous ones were not informative.
Three SPRED1 intragenic polymorphic microsatellites were studied for family 6 (19AT, 19TG, 23AC).
DNA samples were diluted to a concentration of 10 ng/mL and amplified using dedicated primers
and the Taq GOLD polymerase (Thermo Fisher Scientific). The GS-500LIZ (Thermo Fisher Scientific)
marker was used for detection. Sequencing analysis was performed on an ABI Prism 3130 automatic
DNA sequencer (Thermo Fisher Scientific). The results were analyzed with the GeneMapper® v.4.0
software package (Thermo Fisher Scientific). Samples with a unique haplotype were tested for large
NF1 deletion using real-time PCR-based gene dosage of exons 8 and 57, as described in Sabbagh et al.,
2013 [6]. To confirm that variants were de novo, both maternity and paternity were confirmed using a
PowerPlex® 16 HS System (Promega, Madison, WI, USA) kit to analyze the segregation of 15 short
tandem repeat (STR) markers.
2.4. NF1 and SPRED1 Next-Generation Sequencing (NGS)
Experiments were performed at the NGS facility of Cochin Hospital, Paris (Assistance Publique-
Hôpitaux de Paris, France). The techniques were previously described by Pasmant et al., 2015 [17].
Variants were analyzed with NextGENe v.2.4.2.2 (Softgenetics, State College, PA, USA) and Polydiag
(Imagine Institute, Necker Hospital, Paris, France) software.
2.5. DNA and RNA Sequencing with PCR
Polymerase chain reaction (PCR) was performed either for screening purposes or for confirmation of
NGS results on cDNA after reverse transcription of the NF1 transcript, or on DNA samples, respectively.
Selected exons of the NF1 (NM_00267.3) and SPRED1 (NM_152594.2) genes were amplified by PCR
and sequenced as previously described in Sabbagh et al., 2013 [6]. Variants identified by cDNA or
NGS approaches were confirmed using DNA sequencing analysis performed on the corresponding
exon. Sequences were aligned on the reference sequence with Seqscape analysis software v2.5 (Thermo
Fisher Scientific).
2.6. Variant Classification
Variants in the NF1 and SPRED1 genes are reported according to the reference sequences
NM_00267.3 and NM_152594.2, respectively, with the first nucleotide of the first methionine codon
corresponding to the +1 position. Exon numbering is indicated according to the NCBI nomenclature.
Variants were named at the coding DNA and protein levels according to the Human Genome Variation
Society (HGVS) recommendations. In silico predictions of the effect of missense variants were performed
with SIFT, MutationTaster, and Polyphen-2, together with SpliceSiteFinder-like, MaxEntScan, NNSPLICE,
GeneSplicer, and Human Splice Finder embedded in Alamut visual software v.2.7.1 (Interactive
Biosoftware, Rouen, France). CADD scores were obtained for single nucleotide variants (SNVs) with
the 1.4 version. Variant frequency in the general population was checked in the gnomAD and dbSNP
databases. The Leiden Open Variation Database (LOVD) and ClinVar databases were systematically
checked for all variants. An assessment of variants’ pathogenicity was performed according to the
American College of Medical Genetics and Genomics and the Association for Molecular Pathology
(ACMG-AMP) guidelines [18].
3. Results
Pedigrees and clinical data of NF1 patients are shown in Figure 1 and Table 1, respectively. Ages
at last examination are indicated in the corresponding column. All variants were classified according
to the ACMG-AMP guidelines [18] (Table 2).
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Figure 1. Pedigrees of the six NF1 families. NF1 patients with molecular diagnosis, relatives reported as presenting a NF1 phenotype, and patients with a Legius 
syndrome are shown in black, black crosshatching, and gray, respectively. Haplotypes for the NF1 and SPRED1 loci are depicted for the corresponding patients. 
Arrows indicate the propositus in each family. Paternal and maternal ages at conception are indicated above the patient in blue and red, respectively, when 
available.
Figure 1. Pedigrees of the six NF1 families. NF1 patients with molecular diagnosis, relatives reported as presenting a NF1 phenotype, and patients with a Legius
syndrome are shown in black, black crosshatching, and gray, respectively. Haplotypes for the NF1 and SPRED1 loci are depicted for the corresponding patients.
Arrows indicate the propositus in each family. Paternal and maternal ages at co ception are indicated above the patient in blue and red, respectively, when available.
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Table 1. Clinical features of the patients with molecular diagnosis of NF1 in the six families.
Family Patient Sex Age CALS * Freckling Subcutaneous/CutaneousNFs
Plexiform
NFs Lisch Nodules OPG Skeletal Abnormalities Other NF1 Variant
1
IV-1 M 21 >6 No Yes No Yes, bilateral No Mild scoliosis,cubitus valgus
Anemic nevus, learning disabilities,
headaches, myopia c.7084_7085insGA
IV-3 # F 18 >6
Yes, Ax &
In bilateral Yes No Yes, bilateral No Mild scoliosis
Facial nevus, left hemiparesis,
hyperopia, mild intellectual disability c.1885G>A
2
II-1 M 41 >6 No No No No ND None c.6642-5del
III-2 F 14 >6 No No No No ND None c.6642-5del
III-3 # M 2 >6 Yes, Ax bilateral Yes Yes Yes, bilateral Yes Scoliosis
Spinal NFs, xanthogranulomas,
headaches, attention deficit disorder c.4537C>T
3
III-1 F 20 >6 Yes, SM bilateral Yes Yes No No Scoliosis c.5749+5G>A
III-2 # F 15 >6 Yes, Ax bilateral No No Yes Yes None c.2044C>T
4
III-2 F 26 >6 Yes, Ax bilateral Yes No Yes, left No None Short stature, low-set ears c.5154dup
III-5 # M 39 >6 Yes, Ax bilateral Yes No Yes, bilateral No None
Brugada syndrome
(paternal origin) c.3314+2T>C
5
II-6 # F 23 >6 Yes, Ax Yes Yes Yes, bilateral No Scoliosis, short stature Breast cancer, headaches c.3916C>T
IV-1 M 18 >6 Yes Yes Yes No Yes Pseudarthrosis, sphenoidwing dysplasia Learning disabilities c.2376del
6
I-2 F 45 >6 No Yes No ND ND Scoliosis Complete deletion
II-1 M 14 >6 Yes No No No No None
II-2 # F 10 >6 Yes Yes No ND ND None
Hypertelorism, congenital
coronarocardiac fistula Complete deletion
* CALS over 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter in postpubertal individuals. # Propositus. CALS: café-au-lait spots; NFs:
neurofibromas; OPG: optic pathway glioma; Ax: axillary; In: inguinal; SM: sub-mammal; ND: not documented.
Table 2. Variants features and classification according to the ACMG-AMP guidelines.
Gene Variant Exon Protein Consequence StudiedSample Techniques
ACMG-AMP
Classification Evidence of Pathogenicity Reference
NF1
c.7084_7085insGA 48 p.Asn2362Argfs*14 Frameshift DNA + RNA RT-PCR + Sanger Pathogenic PVS1+ PS2+PM2+PP4+PP5 Sabbagh et al., 2013 [6]
c.1885G>A 17 p.Gln616Glyfs*4 Creation of a new 3′ splice site DNA + RNA RT-PCR + Sanger Pathogenic PVS1+PS2+PP3+PP4+PP5 Ars et al., 2003 [19]
c.6642-5del 45 p.Phe2215Hisfs*6 Exon 45 skip DNA + RNA NGS + RT-PCR + Sanger Pathogenic PVS1+PM2+PP4 ND
c.4537C>T 35 p.Arg1513* Premature stop codon DNA + RNA NGS + RT-PCR + Sanger Pathogenic PVS1+PP4+PP5 Side et al., 1997 [20]
c.5749+5G>A 39 p.Ser1850fs*2 Exon 39 skip DNA + RNA NGS + RT-PCR + Sanger Pathogenic PVS1+PS2+PM2+PP3+PP4+PP5 Pros et al., 2008 [21]
c.2044C>T 18 p.(Gln682*) Premature stop codon (predicted) DNA NGS + Sanger Pathogenic PVS1+PS2+PM2+PP4 ND
c.5154dup 37 p.(Phe1719Ilefs*17) Frameshift (predicted) DNA NGS + Sanger Pathogenic PVS1+PM2+PP4 ND
c.3314+2T>C 25 p.? Unknown DNA NGS + Sanger Pathogenic PVS1+PM2+PP4 ND
c.3916C>T 29 p.Arg1306* Premature stop codon DNA + RNA RT-PCR + Sanger Pathogenic PVS1+PS2+PP4+PP5 Park & Pivnick, 1998 [22]
c.2376del 20 p.Asn793Thrfs*28 Frameshift DNA + RNA RT-PCR + Sanger Pathogenic PVS1+PS2+PM2+PP4+PP5 Sabbagh et al., 2013 [6]
SPRED1 c.944C>T 7 p.(Pro315Leu) Missense (predicted) DNA NGS + Sanger Uncertain significance PP3 ND
PVS1: null variant (nonsense, frameshift, canonical ±1 or two splice sites) in a gene where loss of function is a known mechanism of disease; PS2: de novo variant with both maternity and
paternity confirmed; PM2: absent in the general population (controls) in gnomAD and dbSNP; PP3: multiple lines of computational evidence support a deleterious effect on the gene or
gene product (conservation, evolutionary, splicing impact); PP4: patient’s phenotype is highly specific for NF1; PP5: reputable sources (LOVD, ClinVar) report variant as pathogenic. ND:
not described. An asterisk (*) refers to a stop codon. A question mark (?) refers to unknown protein consequences.
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Family 1 is a Sephardic family in which two siblings (patients IV-1 and IV-3) were clinically
diagnosed with NF1. The first child of the kindred (IV-1) had more than eight CALS >1.5 cm and five
CALS <1.5 cm. He also had one subcutaneous NF on the right forearm, an anemic nevus on the left
thigh, bilateral Lisch nodules, mild scoliosis, and learning disabilities with a global IQ of 105 at the
age of 16. His sister (IV-3) had a Sylvian artery stroke when she was eight months old, leading to
permanent left hemiparesis. She was diagnosed with NF1 as she had more than six CALS > 1.5 cm
and multiple smaller CALS, bilateral axillary and inguinal freckling, cutaneous NFs, bilateral Lisch
nodules, and mild scoliosis. The third child of the kindred (IV-2) suffered from intellectual disabilities,
including reading delays. However, he did not show any sign of NF1. The family history revealed the
existence of cysts in several relatives (eyelid cysts in III-7, head cysts in III-8, and renal cysts in III-10),
but no formal diagnosis of NF1 was made in any of them. Molecular diagnosis in the two siblings
IV-1 and IV-3 revealed two independent pathogenic variants in the NF1 gene: c.7084_7085insGA
(p.Asn2362Argfs*14) and c.1885G>A (p.Gln616Glyfs*4), respectively. Sequencing of the parents’ DNA
confirmed that both pathogenic variants occurred de novo. To determine the parental origin of each
variant, long-range PCR was performed in the parents and children. Sequencing of the distal part
of the intron 48 revealed the presence of the c.7126+37C>G variant in both the father (II-6) and his
affected son (IV-1). This benign variant was in cis with the c.7084_7085insGA pathogenic variant found
in the affected son (IV-1), indicating that the de novo c.7084_7085insGA pathogenic variant occurred in
the NF1 paternal allele.
Family 2 is a Caucasian family with a medical history of NF1 in the paternal branch. All the affected
members of family 2 (patients I-2, II-1, III-2, and III-3) had more than six CALS. The grandmother,
I-2, was also described as having developed a scalp tumor. The propositus (III-3) had a more severe
clinical presentation including bilateral axillary freckling and Lisch nodules, OPG, multiple cutaneous
and subcutaneous NFs, and a thoracic PNF. He also developed a spinal NF near the left iliac crest,
xanthogranulomas, scoliosis, and suffered from attention deficit disorder. NGS revealed the presence of
the c.4537C>T, p.(Arg1513*) pathogenic variant in the NF1 gene, which was confirmed at the transcript
level. This variant was not found in the other affected members of the family. The grandmother (I-2),
father (II-1), and sister (III-2) of the propositus carried the c.6642-5del pathogenic NF1 variant, which is
responsible for the exon 45 skip in the NF1 transcript: p.Phe2215Hisfs*6.
In family 3, the propositus (patient III-2) presented with an OPG associated with CALS. NGS
analysis in the propositus identified the c.2044C>T, p.(Gln682*) pathogenic variant in the NF1 gene. Her
cousin (III-1) showed multiple CALS, bilateral sub-mammal freckling, cutaneous and subcutaneous
NFs, one PNF, and scoliosis. Unidentified bright objects (UBOs) were revealed on MRI, but no OPG
was identified. NGS and NF1 transcript analysis identified the c.5749+5G>A, p.Ser1850fs*2 pathogenic
variant in the NF1 gene (leading to the exon 39 skip in the NF1 transcript). Parental DNA studies
showed the de novo origin of both variants in patients III-1 and III-2. Segregation analysis revealed
that the two patients inherited distinct NF1 haplotypes from their respective parents, suggesting that
the two variants occurred on different alleles of the NF1 gene.
Family 4 is a Caucasian family with a medical history of NF1. The propositus (patient III-5) was
a 39-year-old man presenting with CALS, bilateral axillary freckling, Lisch nodules, and cutaneous
and subcutaneous neurofibromas. In addition to NF1, he also suffered from Brugada syndrome
(MIM#601144), inherited from his father. NGS analysis of NF1 in patient III-5 revealed the c.3314+2T>C
NF1 pathogenic variant, which was predicted by in silico tools to alter the NF1 transcript splicing. His
cousin (patient III-2), a 26-year-old woman, was addressed for a molecular confirmation of her clinical
NF1, including CALS, axillary freckling, and cutaneous NFs. NGS analysis revealed the c.5154dup,
p.(Phe1719Ilefs*17) NF1 pathogenic variant in patient III-2. NF1 symptoms were mentioned in several
members of the family, including their respective parents (patients II-3 and II-2), an aunt who died
from a brain tumor (II-1), and her daughter (III-1).
The propositus of family 5 (patient II-6) was a 23-year-old girl with short stature (150 cm), multiple
CALS, axillary freckling, cutaneous and subcutaneous NFs, one plexiform neurofibroma in the lumbar
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fossa, Lisch nodules, and scoliosis. She had developed breast cancer. NGS analysis identified the
c.3916C>T, p.(Arg1306*) NF1 pathogenic variant. Her great-nephew (patient IV-1) was also diagnosed
with NF1. He presented a unilateral OPG at the age of two. He suffered from pseudarthrosis and
sphenoid wing dysplasia. He underwent multiple surgeries for a tibial deformation. Together with
the classical manifestations of the disease, both patients II-6 and IV-1 showed UBOs on MRI. Patient
IV-1 carried a different NF1 pathogenic variant from the propositus: c.2376del, p.Asn793Thrfs*28.
Molecular analysis of the family showed that both NF1 variants occurred de novo. Of note, the father
of the propositus (individual I-1) was described as affected by NF1 (presenting Lisch nodules and
CALS), but he did not carry his daughter’s NF1 variant, nor any other NF1 variant that could have
been detected by our techniques.
In family 6, both the mother (patient I-2) and the daughter (II-2) carried a large deletion of the
NF1 locus. The 10-year-old propositus (II-2) presented multiple CALS, freckling, cutaneous NFs, and a
cardiac malformation. Her mother (I-2) presented CALS, cutaneous NFs, and scoliosis. The propositus’
brother (II-1) only showed multiple CALS and freckling. No pathogenic variant or deletion of the
NF1 gene could be detected in this patient. Real-time quantitative PCR was performed in all three
patients and confirmed the absence of deletion at the NF1 locus for II-1. However, he and his
sister both carried a variant of unknown significance in the SPRED1 gene: c.944C>T, p.(Pro315Leu).
The variant was not detected in their mother, but their father could not be tested. The Pro315 is
evolutionarily conserved and proline presents very different chemical and physical properties from
leucine. The c.944C>T, p.(Pro315Leu) variant is rare in the global population (31/282544 alleles in
gnomAD) and is predominantly found in the African population (30/24958).
4. Discussion
Because of its great phenotypic and genetic heterogeneities, NF1 diagnosis can be challenging.
To date, few cases of two or more different NF1 pathogenic variants in the same family have been
described [6,23,24]. Such cases are challenging and the absence of a familial mutation in a patient
presenting with NF1 clinical features is not sufficient to exclude the diagnosis. On the contrary, the
high mutation rate reported in the NF1 gene [9] should encourage us to search for the occurrence of a
de novo mutation in any suspected case.
Likewise, phenocopies in a family can lead to a delayed diagnosis. As mentioned above for
family 6, Legius syndrome can be mistaken for NF1. The inability to find a NF1 pathogenic variant
should encourage the exploration of the SPRED1 gene when confronted with a mild phenotype. In the
case of family 6, the pathogenicity of the SPRED1 c.944C>T variant could not be ascertained. Its
allelic frequency (31/282544 alleles in GnomAD, predominantly in the African population) and the
lack of data about its de novo origin questioned its role in the development of CALS in patient II-1.
The SPRED1 c.944C>T, p.(Pro315Leu) variant was thus classified as a variant of unknown significance
according to the ACMG-AMP guidelines. Only one case of co-occurrence of NF1 and Legius syndrome
in the same family (with confirmed pathogenic variants in the NF1 and SPRED1 genes) has previously
been reported [25]. Moreover, some NF1 mutations can lead to the development of the overlapping
neurofibromatosis-Noonan syndrome (MIM #601321) [26–31], which combines the typical features of
NF1 (CALS, axillary and inguinal freckling, Lisch nodules, OPG, and neurofibromas) and Noonan
syndrome (short stature, facial dysmorphism, and congenital heart defects, among others). This
observation further reduces the gap between RASopathies and complicates genetic counseling, even
more so when NF1 and Noonan syndrome co-exist in one family [32,33] or in one patient [34–36].
Studies have suggested that most de novo point mutations or small indels have a paternal
origin [37], whereas large deletions are predominantly of maternal origin, as is the case with NF1 [38].
Advanced paternal age can substantially increase this tendency for de novo point mutations, particularly
for mutations occurring in genes implicated in the RAS pathway [39,40]. Indeed, such mutations
stimulate selfish selection during spermatogenesis in a process close to oncogenesis, leading to an
over-representation of spermatozoids carrying these alterations over time. The NF1 gene seems to
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obey this rule, too [41,42]. In the present cases, segregation analysis of family 5 showed that patient
II-6 inherited her mutated allele from her father, as she transmitted her maternal chromosome to
her children, who were not affected. In family 1, haplotype analysis indicated that the de novo
c.7084_7085insGA pathogenic variant occurred in the NF1 paternal allele of patient IV-1. His father
(III-6) was 35 years old at the time of conception.
5. Conclusions
These clinical reports highlight the primordial importance of a systematic approach to the clinical
and molecular diagnoses of NF1 patients. Putative co-occurrence of two or more distinct NF1 mutations
in a pedigree should not be underestimated.
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